Clinical Genomics

Table of Contents

Section 1: Methods

- Overview of technical aspects and chemistries of NGS: Dr Robi Mitra, Washington University School of Medicine.

- Non-selective methods (genome-wide): Dr Mark Bogoski, Harvard Medical School

- Capture based methods (exome, panels) Dr Birgit Funke, Harvard Medical School

- Amplification based methods (panels): Dr Madhuri Hegde, Emory Medical School

- Emerging technologies (Nanopore and others); impact on cost and turnaround time: Dr Elaine Mardis, Washington University School of Medicine.

Section 2: Bioinformatics

- Base calling and alignment; quality metrics; depth of coverage: Dr Carl Volkerding, University of Utah, ARUP labs

- Single nucleotide variants (SNVs): Dr David Spencer, Washington University School of Medicine

- Insertions and deletions (Indels): Drs Eric Duncavage and Haley Abel, Washington University School of Medicine

- Large structural alterations (big deletions, translocations, and so on): Dr Charles Mullighan, St Jude's Cancer Institute

- Copy number variants (CNVs): Dr Mary-Claire King, University of Washington

Section 3: Interpretation

- Reference data bases for disease associations: Dr Heidi Rehm, Harvard Medical School

- Reporting of results; level of evidence for associations; classes of associations: Dr Shashikant Kulkarni, Washington University School of Medicine

- Constitutional diseases (with individual chapters on hypertrophic cardiomyopathy, congenital deafness, blindness, cancer syndromes, and so on): Dr David Bick and Dr David Dimmock, Medical College of Wisconsin

- Cancer (with individual chapters on leukemia, lymphoma, lung cancer, colon cancer, and so on): Dr John Pfeifer, Washington University School of Medicine

Section 4: Regulatory Issues

- Assay validation: Dr Ira Lublin, CDC and Dr Elizabeth Mansfield FDA

- QA/QC/PT issues: Dr Elaine Lyon, University of Utah, ARUP labs

- Consent and privacy issues: Dr James DuBois, Albert Gnaegi Center for Health Care Ethics

Section 5: Reimbursement

- Billing: Andrew Drury and Kris Rickoff, Washington University School of Medicine

Authors

Shashikant Kulkarni Head of Clinical Genomics, Genomics and Pathology Services; Director of Cytogenomics and Molecular Pathology, Washington University School of Medicine, USA. Dr. Shashikant Kulkarni is the Head of Clinical Genomics, Genomics and Pathology Services and also the Director of Cytogenomics and Molecular Pathology at Washington University School of Medicine. In addition, he is Associate Professor of Pathology and Immunology, Pediatrics, and Genetics. His lab's principle research interest is delineation of novel genomic structural and single nucleotide variants in cancer. Somak Roy Assistant Professor, Division of Molecular and Genomic Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Director of Molecular Informatics and the Director of the MGP Fellowship Program, and Associate Laboratory Director of the Division of Molecular and Genomic Pathology. Dr. Somak Roy is an Assistant Professor, in the division of Molecular and Genomic Pathology, at the University of Pittsburgh Medical Center, in Pittsburgh, PA. He is also Director of Molecular Informatics and the Director of the MGP Fellowship Program, and Associate Laboratory Director of the Division of Molecular and Genomic Pathology. Dr. Roy's research is focused on understanding mechanisms of urothelial carcinogenesis and metastasis using next generation sequencing and microarray technologies. He also develops biomedical informatics solutions for optimizing clinical laboratory operations and quality management.